SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

AVC-201

LGND·Ligand Pharmaceuticals
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1b (dose expansion)
Time to market
Likely several years away, if successful. AVC-201 is currently in Phase 1b expansion; a registrational Phase 2/3 trial would follow before any regulatory filing.
Why 2/10
AVC-201 has no hard, dated catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next 12 months. The Phase 1a data was already presented at EHA in June 2026. AVC-201 is also a very small component of Ligand Pharmaceuticals' diversified business (Ligand has over 200 royalty assets including more than 40 marketed products, with ~$285M in projected 2026 revenue). The AvenCell deal was for up to $47 million total, a modest sum for a ~$4B market-cap company.
Actionable Insight NEUTRAL

Watch for Phase 1b expansion interim data from the RevSTAR-123 study, which could come in 2027 at a major medical congress (ASH, EHA). If the dose-dependent efficacy signal holds in a larger cohort with manageable safety, it would strengthen the thesis for AVC-201's registrational potential. However, Ligand's stock will be far more influenced by its Q3 2026 earnings (reported today, Oct 29), guidance, and commercial royalty performance than by any AvenCell news in the near term.

Price Chart

Loading chart...

Executive Summary

AVC-201 is an early-stage allogeneic switchable CAR-T therapy targeting CD123-positive AML, developed by private biotech AvenCell Therapeutics. Ligand Pharmaceuticals (LGND) holds a royalty interest in AVC-201 (and AvenCell's broader pipeline) under a September 2026 financing agreement that committed up to $41 million for mid single-digit to low double-digit royalties. Phase 1a results presented at EHA 2026 showed encouraging safety and dose-dependent efficacy in heavily pretreated AML, with the program now in Phase 1b expansion. For Ligand investors, AVC-201 is a small, early-stage pipeline asset in a portfolio of over 200 programs; it is not a near-term driver of the stock.

How It Works

AVC-201 is an allogeneic (off-the-shelf, donor-derived) CAR-T cell therapy designed to treat acute myeloid leukemia (AML). It targets CD123, a protein found on nearly all AML cells. Unlike standard CAR-T that uses a patient's own cells and stays permanently active, AVC-201 uses a two-component "switchable" system: universal donor CAR-T cells plus a short-acting adapter molecule that can be given to turn activity on and off. This on/off switch aims to reduce toxicity and allow dose control. Because the cells come from healthy donors rather than the patient, manufacturing is faster and potentially cheaper than personalized autologous CAR-T.

Trial Status

AVC-201 completed its Phase 1a dose-escalation portion (RevSTAR-123 study, NCT05949125) with results presented at the EHA 2026 Congress in June 2026. Among 17 heavily pretreated relapsed/refractory AML patients (median 4 prior therapies), the therapy showed a favorable safety profile with no graft-versus-host disease (GvHD), no neurotoxicity, and mostly low-grade cytokine release syndrome (CRS). At the highest dose levels, 3 of 8 evaluable patients achieved complete remission or complete remission with incomplete blood count recovery (CR/CRh), including 2 that became MRD-negative, plus 1 morphologic leukemia-free state. The study has advanced into Phase 1b dose expansion, funded in part by the Ligand financing agreement.

The Two-Sided Case

▲ Bull Case4
Phase 1a results showed a clean safety profile (no GvHD, no neurotoxicity, mostly low-grade CRS) in a very sick AML population, which compares favorably to autologous CAR-T approaches
Dose-dependent activity at higher dose levels produced 3 CR/CRh among 8 evaluable patients, including 2 MRD-negative conversions, suggesting real anti-leukemic efficacy
The allogeneic off-the-shelf design could address key CAR-T commercialization challenges: no patient waiting time, lower manufacturing cost, and controllable on/off activity
Ligand's royalty structure (mid single-digit to low double-digit on worldwide sales) provides leveraged upside if AVC-201 eventually commercializes, with no Ligand R&D spend
▼ Bear Case5
AVC-201 is in Phase 1b with no registrational trial started yet; AML is a notoriously difficult indication and many promising early-stage cell therapies have failed in later trials
The Phase 1a sample size (n=17) is very small and response rates could shrink in larger, more diverse populations
Competition in CD123-targeted AML cell therapy is intensifying, with multiple autologous and allogeneic programs from larger companies
For LGND specifically, AVC-201 represents a tiny fraction of the portfolio value; Ligand's near-term stock is driven by its marketed-product royalties (Captisol, OmniAb, partner drugs) and the XOMA acquisition integration, not early-stage pipeline bets
Ligand's royalty rate is contingent on total funding amount and could be at the low end of the mid single-digit range

Upcoming Catalysts

  • Phase 1b dose-expansion interim data readout (no specific date announced)
  • Potential additional clinical data presentations at future medical congresses

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Ligand Pharmaceuticals PRESS-RELEASE LGND ·Originating report

Sources · 8

Hover a chip for the title
1 onclive.com2 pharmaceutical-technology.com3 investor.ligand.com4 avencell.com5 clinicaltrials.gov6 investor.ligand.com7 labdb.org8 allsci.com